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Abstract 25 
Cholera remains a major risk in developing countries, particularly after natural or man-made 26 
disasters. Vibrio cholerae El Tor is the most important cause of these outbreaks, and is becoming 27 
increasingly resistant to antibiotics, so alternative therapies are urgently needed. In this study, 28 
a single bacteriophage, Phi_1, was used prophylactically and therapeutically to control cholera 29 
in an infant rabbit model. In both cases, phage-treated animals showed no clinical signs of 30 
disease, compared with 69% of untreated control animals. Bacterial counts in the intestines of 31 
phage-treated animals were reduced by up to 4 Log10 CFU/g. There was evidence of phage 32 
multiplication only in animals which received a V. cholerae challenge. No phage-resistant 33 
bacterial mutants were isolated from the animals, despite extensive searching. This is the first 34 
evidence that a single phage could be effective in the treatment of cholera, without detectable 35 
levels of resistance. Clinical trials in human patients should be considered.  36 
Key words: bacteriophage therapy; cholera; phage; infant rabbit; prophylaxis; Vibrio cholerae 37 
Background 38 
V. cholerae has caused seven cholera pandemics since 1817, leading to significant morbidity and 39 
mortality [1]. The first six pandemics (1816 – 1923) were caused by the classical O1 biotype, 40 
while the seventh (1961 - present) was caused by the El Tor biotype [1]. The current pandemic 41 
affects 3-5 million people per annum, causing 21,000 – 143,000 deaths [1,2]. Cholera is 42 
contracted from contaminated food and water in developing countries, where sanitation is 43 
generally inadequate or has been damaged by wars or natural disasters; then transmitted from 44 
person-to-person [3]. 45 
Rehydration therapy reduces mortality and, with antibiotics, can diminish the intensity and 46 
duration of clinical signs and faecal shedding [4]. However, the World Health Organisation now 47 
advises only severe cases of cholera should be treated with antibiotics due to the spread of 48 
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antimicrobial resistance (AMR). Alternative approaches to cholera control are urgently needed, 49 
both for treatment of primary infections, and prevention of secondary spread. Biological control 50 
using bacteriophage (phage) is one alternative, particularly where antibiotic resistance is a 51 
problem [5]. Phage have been used to treat experimental infections in a range of animal models 52 
including mice, chickens, cattle, pigs and lambs [6–8].  53 
In this study, we show that a phage vB_VcholP_1 (Phi_1) belonging to the Podoviridae N4virus 54 
genus was highly effective (p < 0.001) in preventing clinical symptoms of V. cholerae infection in 55 
infant rabbits; the most relevant animal model of cholera in humans. Phage-treatment was 56 
accompanied by significant reductions (p < 0.05) in V. cholerae recovered from several intestinal 57 
compartments compared with untreated control animals.  Notably, we recovered no phage-58 
resistant mutants. This is the first study showing a single phage can prevent clinical symptoms 59 
of cholera infection in this model, with no evidence of resistance development. This study 60 
demonstrates that phage could be a viable alternative treatment for cholera in humans, and 61 
further research to support the application of phage in clinical trials is warranted.  62 
 63 
Methods 64 
Bacteriophage isolation 65 
Phage isolation from lake water samples from several locations in eastern China was performed 66 
as described previously [9] using host V. cholerae O1 strain 2095. Plaques were serially purified 67 
a minimum of five times prior to further use. Additional phage isolates Phi_1, Phi_2 and Phi_3 68 
were obtained from Dr. Tom Cheasty, former Head of the Gastrointestinal Infections Reference 69 
Unit, Public Health England (PHE), UK. Phages Phi_24 and Phi_X29 were purchased from the 70 
Felix d’Herelle Reference Centre for Bacterial Viruses (HER), Quebec, Canada.  71 
Bacteriophage propagation 72 
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Liquid lysates (10 mL) were prepared by inoculating mid-exponential cultures of V. cholerae with 73 
phage at a multiplicity of infection (MOI) of 0.1 and incubating overnight at 37°C in an orbital 74 
shaker at 150 rpm. The lysate was centrifuged (10,000 ×g, 10 min), and filtered (0.45 μm pore-75 
size, Sartorius). Phage titres were determined by plating decimal dilutions of lysates onto 76 
duplicate LBA plates using the agar overlay method [10].  The top agar from plates showing semi-77 
confluent lysis was transferred to a 250 mL centrifuge tube, to which was added 5 mL of SM 78 
buffer per plate. Phage were eluted by incubating at 4°C overnight with gentle shaking, followed 79 
by two rounds of centrifugation (4,000 ×g, 10 min, 4°C), filtration (0.45 μm pore-size) and 80 
storage at 4°C.  81 
Host range profile 82 
Agar overlays of each of the 89 V. cholerae strains (S1_Table) were prepared as described above. 83 
Aliquots (10 μL) of each phage (108 PFU/mL) were spotted onto the lawns and left to dry. The 84 
plates were incubated overnight at 37°C, then scored for lysis as previously reported [11].  85 
One-step growth curve 86 
A mid-exponential-phase culture of V. cholerae was infected with a single phage (MOI 0.1). 87 
Following phage adsorption, the suspension was diluted in LB broth to a final concentration of 88 
104 CFU/mL [9]. Samples (1 mL) of the infected culture were collected at 5 min intervals for 90 89 
min and filtered (0.45 μm pore-size). The phage were enumerated on agar overlays as described 90 
above and the burst size was calculated [12]. 91 
DNA sequencing, assembly and annotation of phage genome 92 
Phage genomic DNA was extracted using a Wizard DNA Clean-Up system (A7280, Promega).  93 
Next generation sequencing was performed by Source Biosciences (Nottingham, UK) and NU-94 
OMICS (Newcastle-upon-Tyne, UK) using the Illumina Miseq platform, 2 × 250-bp paired-end 95 
run. The sequence data was assembled de novo, and single contigs for the phage were generated 96 
using the SPAdes v. 3.1.0 assembler [13] with 120× coverage. The data quality was checked using 97 
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FastQC (Babraham Bioinformatics) and reads were quality trimmed. Genome annotation was 98 
carried out using RAST [14] and Geneious (V6.1.7, Biomatters) software with some manual 99 
curation, which provided the translated sequences of protein-coding regions. These sequences 100 
were used to interrogate the NCBI database using BLASTp. Conserved protein motifs were 101 
identified using a HHpred search of the Pfam database [15]. In the case of BLASTp, proteins were 102 
only assigned to a gene sequence where there was  90% identity with protein motifs in the 103 
database. The tRNA annotation was performed using tRNAscan-SE [16] and ARAGORN [17]. 104 
Post-annotation, the genome was submitted to GenBank (Table S2). The nucleotide sequence 105 
alignments were performed by ClustalW (CLUSTAL 2.1) [18]. The maximum likelihood 106 
phylogenetic analysis was performed using the generalized time-reversible (GTR) model with 107 
FastTree [19] and the phylogeny was visualised using FigTree v.1.4.3 108 
(http://tree.bio.ed.ac.uk/software/figtree). 109 
Transmission Electron Microscopy (TEM)  110 
High titre phage lysates were purified by ultracentrifugation using a CsCl gradient [20]. A 3 µL 111 
sample of CsCl-purified phage was applied to a hydrophilic (glow-discharged) carbon and 112 
Pioloform-coated 300 square mesh copper grid (Agar Scientific Ltd).  Following adsorption (2 113 
min), excess sample was removed with filter paper. The grid was rinsed twice with 5 µL distilled 114 
de-ionised water and the excess was removed before staining with 1% uranyl acetate. Once dry, 115 
the grids were observed on a JEOL JEM-1400 TEM with an accelerating voltage of 100 kV. Digital 116 
images were recorded using a SIS Megaview III digital camera with iTEM software. 117 
Infant rabbit trials 118 
All experimental protocols involving animals were approved by the local Animal Welfare and 119 
Ethical Review Body under UK Home Office project license 70-7495 and performed in 120 
accordance with the UK Animals (Scientific Procedures) Act (1986) and EU Directive 2010/63/EU.  121 
The infant rabbit cholera model  was used to test the effectiveness of phage treatment [21]. 122 
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Time-mated New Zealand White rabbits were obtained from Harlan Laboratories (UK). Following 123 
parturition, litters were housed as a group with the lactating doe for the duration of the study. 124 
Two hours prior to infection with bacteria, 2-day-old rabbits were pre-treated intraperitoneally 125 
with ranitidine (5 mg/kg body weight; GlaxoSmithKline, UK). Oral inoculations of bacteria (0.5 126 
mL volume) and/or phage (1 mL volume) were delivered using separate size 5 French catheters 127 
(Arrow international, USA). The bacterial inoculum was prepared from stationary phase cultures 128 
of pathogenic V. cholerae O1 (biotype classical) 1051 SmR (from the National Institute of Cholera 129 
& Enteric Diseases, Kolkata, India).  These cultures were resuspended in a sodium bicarbonate 130 
solution (2.5 g in 100 mL, pH 9) with a final concentration of approximately 5×108 CFU/animal. 131 
Phage Phi_1 was administered either 6 h before or 6 h after bacterial challenge for prophylactic 132 
and treatment therapies respectively (Table 1). Phage kinetics in the intestinal tract were studied 133 
by dosing rabbits with phage only and collecting samples for analyses at time points 134 
corresponding to 24 h post bacterial infection (i.e. at 18 h to mimic treatment and 30 h to mimic 135 
prophylaxis).  136 
 137 
Diarrhoea was scored using the following scale: none (no signs of faecal contamination or 138 
wetness on their ventral surfaces; upon dissection, the colon contained digesta that appeared 139 
normal (dark green, hard and formed)); mild (soft yellow stools and/or limited areas of wetness 140 
on the rabbits’ fur; upon dissection, digesta was missing from the colon or appeared yellow, soft 141 
and unformed; some fluid accumulation in the caecum), and severe (extensive areas of wetness 142 
on their tails and ventral surfaces; upon dissection no digesta was found in the colon and the 143 
cecum and small intestine contained large quantities of clear fluid). Control and treatment group 144 
litters were housed separately to avoid cross-contamination and at least 3 litters were used for 145 
each treatment strategy. 146 
Animals were anaesthetised 24 h post infection using inhalation isoflurane (Isofol®, Abbott, UK) 147 
and euthanized with intracardiac KCl (15% w/v, MercuryPharma, Ireland) at 2.5 mL/100 g body 148 
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weight. Tissue segments (1 cm) were collected from the upper (I1), middle (I2) and lower (I3) 149 
small intestine and caecal fluid (CF) was collected by gravity. The tissue samples were 150 
mechanically homogenised between sterile glass slides in 2 mL sterile phosphate buffered saline 151 
(PBS). Caecal fluid accumulation ratios (FAR) were calculated as previously reported [21]. When 152 
no CF was collected, caecal content was used instead to report numbers of bacteria. For 153 
bacterial enumeration, samples were decimally diluted and triplicate 10 µL aliquots spotted 154 
onto TSA containing streptomycin (200 µg/mL). In addition, 100 µL of the original sample, and 155 
in some instances, a 5x concentration of this volume, was spread onto the same media to enable 156 
lower numbers of cells to be detected. Phage enumeration was performed by spotting 10 µL 157 
volumes of filtered (0.45 µm syringe filters) intestinal content on to lawns of the host strain. All 158 
plates were incubated at 37°C for 24 h before examining for colonies or plaques.  159 
Phage-resistance  160 
Presumptive V. cholerae isolates recovered from phage-treated and control animal groups were 161 
confirmed by PCR [22] and streaked on both LB agar plates, with and without supplementation 162 
with Phi_1 (1×109 PFU/mL). The plates were incubated at 37oC for 24 h before examining for 163 
colonies.  164 
Statistical analysis 165 
Rabbit disease scores and caecal FARs were analysed using Fisher’s exact test and one-way 166 
ANOVA, respectively. All bacterial and phage count data were log10-transformed prior to 167 
statistical analysis.  Bacterial count data were analysed using the Krushal-Wallis test with Dunn’s 168 
post hoc multi-comparison test (Graphpad Prism, version 5.02). Differences in phage count data 169 
were analysed using the two-sample Mann Whitney U test (using Minitab, v. 17.2.1, 170 
Pennsylvania, USA).  171 
 172 
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Results  173 
Phage isolation, morphological characterization and selection for use as a 174 
therapeutic 175 
Seven phage were isolated from samples of lake water collected from China. A further five phage 176 
were obtained from existing collections. The morphological characteristics of each phage were 177 
used to determine a provisional taxonomic classification (Table 2).   178 
 179 
The host range and burst size of each phage were determined using a collection of 89 V. cholerae 180 
O1, O139 and non-O1/O139 strains (S1 Table) in order to identify candidates best suited for 181 
therapeutic application. The three Myoviridae phage (Phi_2, Phi_24 and Phi_X29) exhibited 182 
much narrower host ranges (1.1 to 4.4%) than Podoviridae or Siphoviridae phages (Table 1). The 183 
different phage families did not cluster according to latent period or burst size.  184 
In addition to exhibiting a broad host range and large burst size, phage therapy candidates 185 
should not possess genes associated with virulence or lysogeny. Therefore, we sequenced the 186 
phage and examined their genomes for proteins of known function. The Genbank accession 187 
numbers for all phage genomes are provided in S2 Table. Sequencing revealed that none of the 188 
phage genomes contained known virulence genes.  However, all of the phage, exceptPhi_1 and 189 
Phi_3, contained integrase sequences, suggesting they may be temperate phage and unsuitable 190 
for therapeutic applications.    Given that Phi_1 exhibited a slightly broader host range than 191 
Phi_3, we focused our efforts on Phi_1 (an electron micrograph of Phi_1 presented in Fig 1). The 192 
Phi_1 genome is 66.7 kb and contains 110 genes (S3 Table). Amongst these, 12 were listed as 193 
early or middle genes associated with metabolism and replication, 6 could be grouped into the 194 
late genes related to head morphogenesis and host cell lysis and the remaining 92 genes 195 
encoded hypothetical proteins. BlastN analysis revealed that phage Phi_1 was most closely 196 
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related to two N4-like viruses, Vibrio phage JA1 (Genebank: NC_021540.1) and VCO139 197 
(Genebank: KC438283.1), with 97 % pairwise identity and similar G+C content (34.5% versus 198 
34.6%). No tRNA sequences were detected in the Phi_1 genome in contrast to a single tRNA in 199 
each of JA1 and VCO139. To further resolve the taxonomic placement of Phi_1, phylogenetic 200 
analysis was performed comparing the genome sequence of Phi_1 with the available published 201 
genome sequences of phage in the genus N4virus. Phylogeny showed that Phi_1 grouped with 202 
VCO139 and JA-1, with the only classified species of the genus N4virus, Escherichia phage N4, 203 
located in a distant clade (Fig 2). Thus, we have identified a previously undescribed Podoviridae 204 
N4likevirus with characteristics that are favourable for phage therapy including being effective 205 
against a range of clinical V. cholerae strains grown under laboratory conditions. 206 
Effectiveness of Phi_1 to control experimental cholera in infant rabbits 207 
To assess whether phage Phi_1 could be used to control experimental cholera, therapeutic and 208 
prophylactic studies were performed using the infant rabbit cholera model [23]. For the 209 
therapeutic trials, groups of infant rabbits were orally infected with approximately 8×108 CFU of 210 
SmR V. cholerae O1 strain 1051 and treated with phage (109 PFU) 6 h after infection. Control 211 
animals receiving only V. cholerae developed signs of disease as reported previously for rabbits 212 
infected with V. cholerae O1 [23]. Signs included the production of watery diarrhoea, loose stool 213 
and/or notable caecal fluid accumulation occurring in the majority (11 of 17) of infected animals 214 
(Table 3). In marked contrast, none of the phage-treated animals (0 of 19) showed signs of 215 
disease at 24 h post infection. Caecal fluid accumulation ratios (FAR) were 6-fold higher in 216 
diseased control animals compared to phage-treated animals (mean ± standard error: 0.39 ± 217 
0.08 versus 0.06 ± 0.01; p < 0.001), consistent with the lack of disease.  218 
 219 
Furthermore, phage treatment was associated with a significant reduction in the number of V. 220 
cholerae recovered from the intestine compared to the control group, with no detectable 221 
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colonies recovered in more than half the animals (Figs 2A-C). Median reductions of 2-4 Log10 222 
CFU/g V. cholerae were recorded in different intestinal compartments, including in caecal 223 
content (Fig 3D). This, together with the low volumes of fluid evident in the intestine, would lead 224 
to a marked reduction in the number of organisms shed from the host.  225 
We also assessed the ability of Phi_1 to be used prophylactically. In these studies, infant rabbits 226 
were administered 109 PFU phage 6 h prior to infection with approximately 5×108 CFU/animal 227 
V. cholerae. Reflecting the therapeutic trials, phage-treated animals showed no symptoms of 228 
disease, and exhibited significant reductions in recoverable V. cholerae and intestinal fluid 229 
compared with untreated control animals (Table 2 and Figs 2A-D).  Overall, these data indicate 230 
that Phi_1 is effective at killing V. cholerae in several intestinal compartments both prior to and 231 
following challenge with virulent V. cholerae.   232 
Phage Phi_1 amplifies in the intestine and did not give rise to phage-resistant mutants  233 
When administered 6 h after V. cholerae infection, approximately 106-107 PFU/g of phage were 234 
recovered in the intestine of the animals, approximately 100-fold higher than in animals given 235 
phage only (range 104 – 106 PFU/g) (Table 3). Slightly lower levels of phage were recovered 236 
during the prophylaxis experiments, most likely reflecting the increased time for transit through 237 
the intestine prior to bacterial inoculation (18h and 30h, respectively). However, in both cases, 238 
significant amplification of phage was recorded in most intestinal compartments, leading to a 239 
multiplicity of infection (MOI) throughout the intestinal tract of about 1-2 phage per V. cholerae 240 
cell (Table 4). Finally, this data suggests that significant numbers of phage (104-105 PFU/g) were 241 
recoverable from the intestine up to 30 h post administration, even in the absence of V. 242 
cholerae.  243 
 244 
V. cholerae colonies recovered from all the in vivo experiments were tested for their 245 
susceptibility to phage Phi_1 to determine levels of phage-resistance. Somewhat surprisingly, 246 
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none of the colonies grew in LB media supplemented with 109 PFU of phage Phi_1, indicating 247 
that they remained sensitive to the phage. Moreover, attempts to generate phage-resistant 248 
mutants in vitro using plate-based methods were not successful suggesting that the as-yet-249 
uncharacterised phage Phi_1 receptor is important for V. cholerae viability under these 250 
conditions. 251 
 252 
Discussion 253 
Here, we show for the first time, that oral administration of a single Podoviridae phage could 254 
prevent clinical cholera symptoms in infant rabbits without the development of phage 255 
resistance. Our findings provide further evidence that phage can both reduce the severity of 256 
disease and limit spread of the organism to the environment. Given the well-documented 257 
challenges associated with the emergence of antibiotic-resistant bacteria, phage may yet 258 
provide a viable alternative to antibiotics.  259 
The strain of V. cholerae used has been shown experimentally by this group to result in cholera 260 
using the infant rabbit model [21], with fluid accumulation in the small intestine, perianal 261 
staining and dehydration resulting in death if humane termination is not carried out. The infant 262 
rabbit model combines sensitivity with a greater convenience than other whole animal models 263 
such as the ligated intestinal loop model in adult rabbits [24] or mouse models [21].  264 
Given that animals receiving only bacteriophage had detectable levels of phage in their 265 
intestines for at least 24 h; prophylaxis experiments with a longer interval between phage and 266 
bacteria administration would be worth assessing. However, as the rabbits are in an enclosed 267 
environment, environmental contamination with phage may occur with the ingestion and re-268 
ingestion of phage from the mother’s skin or the bedding. 269 
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Camilli and colleagues published a study describing the prophylactic use of a 3-phage (ICP) 270 
cocktail to treat cholera [25]. They recorded a marked reduction in disease and V. cholerae 271 
recovered from rabbits given the phage cocktail.  However, in contrast to the present study, 272 
they also recovered phage-resistant mutants. Susceptibility profiling of the in vivo passaged V. 273 
cholerae against the individual phage present in the ICP cocktail revealed that resistance differed 274 
depending on the animal host as well as over time. The phage used in the Camilli study were all 275 
members of the Podoviridae, a genus previously identified as containing phage that make 276 
‘better’ in vivo therapeutic agents [26]. Rational and systematic evaluation of phage 277 
characteristics according to morphology, genomics and a number of cultural phenotypes 278 
including latent period, burst size and host-range, appears to be critical in the selection of phage 279 
as therapeutic agents. Latent period, burst size and the presence of a DNA-dependent RNA 280 
polymerase (DdRp) have all been found to correlate with in vivo efficacy in controlling 281 
experimental E. coli infections [26]. Both phage Phi_1 and ICP3 encode a specific RNA 282 
polymerase which could improve their effectivity in vivo. However, it could also be that phage 283 
Phi_1 uses a crucial receptor for V. cholerae survival in the intestinal tract, such as the O1 284 
lipopolysaccharide antigen. It is well known that phase variable mutants of O1 receptor are 285 
protected from phage infection, but become attenuated [27]. Selecting phage which target 286 
surface virulence determinants can be an effective approach, as phage-resistant mutants are 287 
often attenuated.  In one study, using E. coli phage targeting the K1 capsule resulted in the 288 
recovery of acapsular but attenuated mutants [8]. The potential development of resistance is a 289 
concern if phage are applied in the field, since oral administration to patients may result in 290 
extensive shedding of bacteria and phage in the environment, potentially resulting in 291 
recirculation of phage-resistant mutants. In some circumstances, this could be avoided by 292 
limiting phage administration to cases in clinics and composting the evacuated faeces.  293 
Alternatively, the impact of phage recirculation could be minimised by using different phage 294 
   
 
13 
preparations that target different receptors, or combinations of receptors, in order to limit the 295 
emergence of resistant strains.  296 
 297 
Two previous studies of phage therapy to treat cholera in small groups of human patients found 298 
either little clinical effect [28], or the requirement for large phage doses (>1015 PFU) [29].  299 
However, the phage used were not well-characterised, and some appeared to be temperate and 300 
ill-suited for therapy.  Additionally, neither study neutralised stomach acid prior to phage 301 
administration, which may significantly affect the results. Both studies used phage cocktails 302 
which, if combined carefully, may offer some protection against the emergence of resistant 303 
mutants. However, the performance of phage cocktails may be no better than individual phages 304 
[30], and could be worse. The use of cocktails requires a balance to be struck between the 305 
practical limitations of preparing lysates of many different phage, and the need to include 306 
sufficient phage to minimise the emergence of resistant mutants.  Principally, this should be 307 
done through genomic and phenotypic analysis to combine compatible phage which target 308 
different receptors.     309 
Characterisation of the interaction of Phi_1 and its receptor(s) may provide some clues as to 310 
why phage-resistant mutants were not recovered. Prophylactic and therapeutic trials with Phi_1 311 
need to be performed in human volunteers to determine if this treatment is viable. Should this 312 
prove successful, bacteriophage therapy could be deployed relatively easily to remote and 313 
underserved communities in developing countries due to the ease and speed with which phage 314 
can be prepared, using basic laboratory equipment. Alternatively, preparations of phage can be 315 
made using lyophilisation, spray-drying, emulsification and microencapsulation, which remain 316 
stable for years (recently reviewed in [31]). Phage therapy has significant potential to save 317 
hundreds or thousands of lives during outbreaks of cholera which follow natural and man-made 318 
disasters; an aim strongly worth pursuing.      319 
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Figure 1.  Electron micrograph of Podoviridae phage Phi_1.  406 
Figure 2. The maximum likelihood phylogenetic comparison of vB_VcholP_1 with the 407 
published genome sequences of phage species from genus N4virus. The maximum likelihood 408 
phylogenetic analysis was carried out using the generalized time-reversible (GTR) model with 409 
FastTree and the phylogeny was visualised using FigTree. 410 
Figure 3. Efficacy of phage Phi-1 in reducing V. cholerae O1 colonisation of the infant rabbit 411 
intestine. Rabbits were administered 1 × 109 PFU phage Phi-1 orally, 6 h pre- or post- infection 412 
with 5 – 8 × 108 CFU V. cholerae O1.  Viable V. cholerae were recovered from the upper (A), mid 413 
(B) and distal (C) small intestine and in caecal fluid (D) at 24 h post bacterial infection following 414 
tissue homogenisation and plating on selective media. Symbols represent individual animals, 415 
with open symbols representing samples where the number of recoverable colonies was below 416 
the limit of detection.  The number of animals in each group was 17, 22 and 19 respectively, and 417 
each group was derived from 3 independent litters. Bars represent the median and interquartile 418 
   
 
19 
range. Data were compared using the Kruskal Wallis test followed by Dunn’s post hoc multiple 419 
comparisons test. 420 
 421 
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Table 1. Litter size, bacterial and phage dose and treatment inoculation schedule of rabbit experiments. 
Group 
Number 
of 
animals 
V. cholerae 
inoculum 
(CFU/animal) 
Phage inoculum 
(PFU/animal) 
Treatment schedule 
Control 1 6 7×108 -  
- 
 
Control 2 5 2×108 - 
Control 4 7 6×108 - 
Therapeutic 1 10 1×109 1×109 
6-8 h post-bacterial 
infection 
Therapeutic 2 6 4×108 1×109 
Therapeutic 3 4 1×109 1×109 
Prophylactic 1 10 5×108 1×109 6 h prior-bacterial 
infection 
 
Prophylactic 2 6 5×108 1×109 
Prophylactic 3 6 8×108 1×109 
Therapeutic control 8 - 1×109 
6-8 h post-bacterial 
infection 
Prophylactic control 6 - 1×109 
6 h prior-bacterial 
infection 
 
Table 1
Table 2. Bacteriophage source and characterization including host range and one-step growth curve. 
Phage full name 
Short 
name 
Phage source Genus 
Head 
diamet
er (nm) 
a 
Tail 
length 
(nm) a 
Host 
range (%) 
Latent 
period 
(min) a 
Burst size 
(PFU) a 
vB_VcholP_QH Phi_QH Qing He river 
(Beijing) 
Podoviridae 51 ± 
0.1 
12 ± 
0.0 
84.6 12 ± 4.0 92 ± 09 
vB_VcholP_CJY Phi_CJY Cui Jia Yao 
river (Beijing) 
Podoviridae 54 ± 
0.1 
10 ± 
0.0 
16.5 13 ± 4.3 182 ± 62 
vB_VcholP_H1 Phi_H1 Fu Jia Wan 
lake (Hubei) 
Podoviridae 56 ± 
0.1 
11 ± 
0.0 
37.3 6 ± 2.3 89 ± 32 
vB_VcholP_H2 Phi_H2 Ye Zhi Hu lake 
(Hubei) 
Podoviridae 57 ± 
0.1 
12 ± 
0.0 
18.7 15 ± 1.6 63 ± 13 
vB_VcholP_H3 Phi_H3 Nan Hu lake 
(Hubei) 
Podoviridae 55 ± 
0.1 
12 ± 
0.0 
70.3 7 ± 3.5 126 ± 18 
vB_VcholP_J2 Phi_J2 Yudai He river 
(Jiangxi) 
Podoviridae 54 ± 
0.1 
12 ± 
0.0 
16.5 5 ± 0.6 34 ± 13 
vB_VcholP_J3 Phi_J3 Yudai He river 
(Jiangxi) 
Podoviridae 52 ± 
0.1 
11 ± 
0.0 
76.9 14 ± 1.5 56 ± 17 
vB_VcholP_1 Phi_1 PHE Podoviridae 34 ± 
0.2 
13 ± 
0.1 
67.0 12 ± 0.0 43 ± 05 
vB_VcholM_2 Phi_2 PHE Myoviridae 53 ± 
0.2 
118 ± 
0.4 
4.4 14 ± 1.6 6 ± 01 
vB_VcholS_3 Phi_3 PHE Siphoviridae 75 ± 
0.1 
156 ± 
0.2 
62.6 13 ± 4.1 54 ± 26 
vB_VcholM_24 Phi_24 HER Myoviridae 64 ± 
0.1 
69 ± 
0.1 
1.1 4 ± 0.0 87 ± 26 
Table 2
vB_VcholM_X29 Phi_X29 HER Myoviridae 64 ± 
0.1 
95 ± 
0.3 
2.2 16 ± 0.0 77 ± 16 
aMean of three independent measurements ± Standard Error.  
Public Health England (PHE), Felix d’Herelle Reference Centre for Bacterial Viruses (HER). 
 
Table 3. Disease status and fluid accumulation ratios (FAR) in infant rabbits treated with phage Phi_1 pre- and 
post- infection with V. cholerae O1. 
Treatment None Phage administrationa  
  Therapeutic Prophylactic  
Disease (%) 69 0c 0c 
Disease scoreb    
Severe 1 0 0 
Mild 10 0 0 
None 6 19 22 
Total no. animals 17 19 22 
FARd 0.39 ± 0.31 0.06 ± 0.05d 0.04 ± 0.02d 
 aPhage Phi_1 was orally administered 6 h before (prophylactic) or 6 h after (therapeutic) the bacteria.   
bNumber of rabbits with disease as described in the text. 
cFisher’s exact test was used to compare the disease in animals given phage Phi-1, pre- or post-infection with V. 
cholerae O1. p < 0.001. 
dFluid accumulation ratio (FAR) is calculated from the weight of the caecal fluid to the tissue for each animal.  
eOne way ANOVA followed by Dunnett’s multiple comparison test was used to analyse the values.  p < 0.001. 
 
Table 3
Table 4. Bacteriophage concentration, production and MOI during prophylactic and therapeutic treatments. 
Samplee Therapeutic treatment phage concentration (Log10 
PFU/g)a 
Prophylactic treatment phage concentration (Log10 
PFU/g)a 
Control† Treatment Phage 
production 
MOI Control‡ Treatment Phage 
production 
MOI 
I1 4.2 ± 1.8 6.4 ± 0.3d 2.2 1.9 4.7 ± 0.4 5.1 ± 0.2 0.4 1,8 
I2 5.3 ± 0.9 6.6 ± 0.2c 1.3 2.0 4.6 ± 0.3 5.1 ± 0.1 0.5 1,8 
I3 4.8 ± 0.8 6.8 ± 0.3d 2.0 1.7 5.0 ± 0.6 5.7 ± 0.2b 0.7 1,8 
MC 6.6 ± 0.5 7.6 ± 0.7c 1.0 2.0 5.7 ± 0.6 6.7 ± 0.2c 0.9 2,1 
CF 6.1 ± 2.5  7.8 ± 0.3b 1.7 2.3 5.4 ± 0.7 7.1 ± 0.1d 1.7 2,0 
aMean concentration ± Standard error. Phage Phi_1 was orally administered following the therapeutic or 
prophylactic schedule. Prophylaxis, control n=6, treatment n=22. Therapeutic control n=8, treatment n=18. Mann 
Whitney U test was used to compare values between groups. b (p < 0.05), c (p < 0.01) and d (p < 0.001).    
eValues from Upper small intestine (I1), mid small intestine (I2), low small intestine (I3), mid colon (MC) and caecal 
fluid (CF) are shown.  
†Animals given only Vibrio cholerae 1051. 
‡Animals given only phage Phi_1. 
 
Table 4
Strain Biotype Collection Source Year of Isolation Sample Type Phi_1
10 Vibrio cholerae non‐O1/non‐O139 Professor Brendan Wren and Muhammad Ali, LSHTM Rawalpindi, Punjab ‐ Pakistan 2011 Sewage ‐
238 Vibrio cholerae non‐O1/non‐O139 Professor Brendan Wren and Muhammad Ali, LSHTM Khewra, Punjab ‐ Pakistan 2011 Salt mine ‐
404 Vibrio cholerae non‐O1/non‐O139 Professor Brendan Wren and Muhammad Ali, LSHTM Islamabad, Federal Capital ‐ Pakistan 2011 Unknown ‐
406 Vibrio cholerae non‐O1/non‐O139 Professor Brendan Wren and Muhammad Ali, LSHTM Islamabad, Federal Capital ‐ Pakistan 2011 Unknown ‐
709 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Murree, Punjab ‐ Pakistan 2011 Clinical +
719 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Murree, Punjab ‐ Pakistan 2011 Clinical +
722 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Murree, Punjab ‐ Pakistan 2011 Clinical +
729 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Murree, Punjab ‐ Pakistan 2011 Clinical +
732 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Murree, Punjab ‐ Pakistan 2011 Clinical +
736 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Murree, Punjab ‐ Pakistan 2011 Clinical +
739 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Murree, Punjab ‐ Pakistan 2011 Clinical ‐
742 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Murree, Punjab ‐ Pakistan 2011 Clinical +
750 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Chamman, Baluchistan ‐ Pakistan 2011 Clinical ‐
751 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Larkana, Sindh ‐ Pakistan 2011 Clinical +
752 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Muzaffargarh, Punjab ‐ Pakistan 2011 Clinical +
753 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Zoab, Baluchistan ‐ Pakistan 2011 Clinical +
754 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Badin, Sindh ‐ Pakistan 2011 Clinical +
755 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Rahimyar Khan, Punjab ‐ Pakistan 2011 Clinical +
756 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Dadu, Sindh ‐ Pakistan 2011 Clinical +
757 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Bahawalnagar, Punjab ‐ Pakistan 2011 Clinical +
758 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Sanghar, Sindh ‐ Pakistan 2011 Clinical +
759 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Larkana, Sindh ‐ Pakistan 2011 Clinical +
760 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Larkana, Sindh ‐ Pakistan 2011 Clinical ‐
761 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Qasoor, Punjab ‐ Pakistan 2011 Clinical +
762 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Muzaffarabad, Azad Jammu and Kashmir ‐ Pakistan 2011 Clinical +
763 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Sukkur, Sindh ‐ Pakistan 2011 Clinical ‐
764 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Rawalpindi, Punjab ‐ Pakistan 2011 Clinical +
765 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Chakwal, Punjab ‐ Pakistan 2011 Clinical ‐
767 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Rawalpindi, Punjab ‐ Pakistan 2011 Clinical +
768 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Islamabad, Federal Capital ‐ Pakistan  2011 Clinical +
769 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Peshawar, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical +
770 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Swabi, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical +
771 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Multan, Punjab ‐ Pakistan 2011 Clinical +
772 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Multan, Punjab ‐ Pakistan 2011 Clinical +
773 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Sialkot, Punjab ‐ Pakistan 2011 Clinical +
774 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Islamabad, Federal Capital ‐ Pakistan 2011 Clinical +
775 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Kamalia, Punjab‐ Pakistan 2011 Clinical ‐
776 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Okara, Punjab ‐ Pakistan 2011 Clinical ‐
1051 Vibrio cholerae O1 Classical Felix d’Herelle reference center for bacterial virues National Institute of Cholera and Enteric Diseases, Kolkata ‐ India 1979 Clinical +
2095 Vibrio cholerae O1 El Tor Inaba Dr. Jingliang Su, CAU, China Beijing, China 2011 Clinical ‐
A‐4 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Attock, Punjab ‐ Pakistan 2011 Clinical +
BW‐5 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Chiniot, Punjab ‐ Pakistan 2011 Clinical +
CS‐1 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Charsada, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical +
CS‐12 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Charsada, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical +
CS‐15 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Charsada, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical +
CS‐16 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Charsada, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical +
CS‐18 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Charsada, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical +
CW‐1 Vibrio cholerae non‐O1/non‐O139 Professor Brendan Wren and Muhammad Ali, LSHTM Bahawalpur, Punjab ‐ Pakistan 2011 Fish ‐
D‐1 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM D I Khan, Khyber Pakhtunkhwa ‐ Pakistan 2010 Clinical ‐
D‐13 Vibrio cholerae non‐O1/non‐O139 Professor Brendan Wren and Muhammad Ali, LSHTM D I Khan, Khyber Pakhtunkhwa ‐ Pakistan 2010 Clinical ‐
D‐25 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM D I Khan, Khyber Pakhtunkhwa ‐ Pakistan 2010 Clinical +
D‐30 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM D I Khan, Khyber Pakhtunkhwa ‐ Pakistan 2010 Clinical +
D‐56 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM D I Khan, Khyber Pakhtunkhwa ‐ Pakistan 2010 Clinical +
D‐59 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM D I Khan, Khyber Pakhtunkhwa ‐ Pakistan 2010 Clinical +
DN‐4 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Nowshera, Khyber Pakhtunkhwa ‐ Pakistan 2010 Clinical +
F‐5 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Rawalpindi, Punjab ‐ Pakistan 2011 Clinical +
F‐6 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Rawalpindi, Punjab ‐ Pakistan 2011 Clinical +
FB‐O1 Vibrio cholerae non‐O1/non‐O139 Professor Brendan Wren and Muhammad Ali, LSHTM Islamabad, Federal Capital ‐ Pakistan 2011 Drinking water ‐
FN‐2 Vibrio cholerae non‐O1/non‐O139 Professor Brendan Wren and Muhammad Ali, LSHTM Islamabad, Federal Capital ‐ Pakistan 2011 Sewage ‐
FN‐4 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Islamabad, Federal Capital ‐ Pakistan 2011 Sewage ‐
FN‐5 Vibrio cholerae non‐O1/non‐O139 Professor Brendan Wren and Muhammad Ali, LSHTM Islamabad, Federal Capital ‐ Pakistan 2011 Clinical ‐
GB‐39 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Gilgit, Gilgit Baltistan ‐ Pakistan 2011 Clinical +
HH‐1 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Hyderabad, Sindh ‐ Pakistan 2010 Clinical +
HH‐14 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Hyderabad, Sindh ‐ Pakistan 2010 Clinical +
HH‐15 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Hyderabad, Sindh ‐ Pakistan 2010 Clinical +
HH‐4 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Hyderabad, Sindh ‐ Pakistan 2010 Clinical +
Ht‐10 Vibrio cholerae non‐O1/non‐O139 Professor Brendan Wren and Muhammad Ali, LSHTM Rawalpindi, Punjab ‐ Pakistan 2011 Drinking water ‐
Ht‐10A Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Rawalpindi, Punjab ‐ Pakistan 2011 Drinking water ‐
J‐1 Vibrio cholerae non‐O1/non‐O139 Professor Brendan Wren and Muhammad Ali, LSHTM Islamabad, Federal Capital ‐ Pakistan 2011 Sewage ‐
KCH‐18 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Karachi, Sindh ‐ Pakistan 2010 Clinical +
KPD‐3 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Khairpur, Sindh ‐ Pakistan 2010 Clinical +
KtH‐4 Vibrio cholerae non‐O1/non‐O139 Professor Brendan Wren and Muhammad Ali, LSHTM Jamshoro, Sindh ‐ Pakistan 2010 Clinical +
KTH‐7 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Jamshoro, Sindh ‐ Pakistan 2010 Clinical +
M14 Vibrio cholerae O1 El Tor Inaba Neil Williams, University of Bristol Unknown Unknown Clinical +
N‐10 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Nowshera, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical ‐
N‐5 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Nowshera, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical +
N‐7 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Nowshera, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical +
NP‐14 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Nowshera, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical ‐
NP‐3 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Nowshera, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical +
NP‐5 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Nowshera, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical +
NP‐6 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Nowshera, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical ‐
NP‐7 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Nowshera, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical +
O395NT Vibrio cholerae O1 El Tor Ogawa Neil Williams, University of Bristol Unknown Unknown Unknown +
O5 Vibrio cholerae non‐O1/non‐O139 Professor Brendan Wren and Muhammad Ali, LSHTM Rawalpindi, Punjab ‐ Pakistan 2011 Sewage ‐
P‐1 Vibrio cholerae non‐O1/non‐O139 Professor Brendan Wren and Muhammad Ali, LSHTM Peshawar, Khyber Pakhtunkhwa ‐ Pakistan 2011 Sewage ‐
PS‐18 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Peshawar, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical ‐
PS‐25 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Peshawar, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical +
PS‐7 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Peshawar, Khyber Pakhtunkhwa ‐ Pakistan 2011 Clinical +
RG‐6 Vibrio cholerae O1 El Tor Ogawa Professor Brendan Wren and Muhammad Ali, LSHTM Rawalpindi, Punjab ‐ Pakistan 2010 Clinical +
Supplementary Table 1
V. cholerae phage GenBank accession number 
vB_VcholP_QH KM612259 
vB_VcholP_CJY KM612260 
vB_VcholP_H1 KM612261 
vB_VcholP_H2 KM612262 
vB_VcholP_H3 KM612263 
vB_VcholP_J2 KM612264 
vB_VcholP_J3 KM612265 
vB_VcholP_1 KP280062 
vB_VcholM_2 KJ545483.2 
vB_VcholS_3 KP280063 
vB_VcholM_24 KJ572844.2 
 
Supplementary Table 2
Locus tag Function Start:End of CDS Orientation Size (bp) 
AVV30_gp001 
hypothetical 
protein 183:389 forward 207 
AVV30_gp002 
hypothetical 
protein 389:601 forward 213 
AVV30_gp003 
hypothetical 
protein 598:990 forward 393 
AVV30_gp004 
hypothetical 
protein 1071:1235 forward 165 
AVV30_gp005 
hypothetical 
protein 1373:1624 forward 252 
AVV30_gp006 
hypothetical 
protein 1661:1903 forward 243 
AVV30_gp007 
hypothetical 
protein 1900:2121 forward 222 
AVV30_gp008 
hypothetical 
protein 2172:2309 forward 138 
AVV30_gp009 
hypothetical 
protein 2372:2629 forward 258 
AVV30_gp010 
hypothetical 
protein 2801:2986 forward 186 
AVV30_gp011 
hypothetical 
protein 3100:3333 forward 234 
AVV30_gp012 
hypothetical 
protein 3389:3655 forward 267 
AVV30_gp013 
hypothetical 
protein 3658:3897 forward 240 
AVV30_gp014 
hypothetical 
protein 3902:4141 forward 240 
AVV30_gp015 
hypothetical 
protein 4202:4408 forward 207 
AVV30_gp016 
DNA-directed 
RNA polymerase 
RNAP1 4427:5368 forward 942 
AVV30_gp017 
hypothetical 
protein 5368:5583 forward 216 
AVV30_gp018 
hypothetical 
protein 5602:6051 forward 450 
AVV30_gp019 
hypothetical 
protein 6193:6750 forward 558 
AVV30_gp020 
DNA-directed 
RNA polymerase 
RNAP2 6918:7703 forward 786 
AVV30_gp021 
hypothetical 
protein 7755:7937 forward 183 
AVV30_gp022 
hypothetical 
protein 7938:8147 forward 210 
AVV30_gp023 
hypothetical 
protein 8180:8368 forward 189 
AVV30_gp024 
hypothetical 
protein 8382:8585 forward 204 
AVV30_gp025 
hypothetical 
protein 8590:8718 forward 129 
AVV30_gp026 
hypothetical 
protein 8727:8972 forward 246 
AVV30_gp027 
hypothetical 
protein 8945:9217 forward 273 
Supplementary Table 3
AVV30_gp028 
N-
acetylmuramoyl-
L-alanine amidase 9203:9727 reverse 525 
AVV30_gp029 
hypothetical 
protein 9751:10047 forward 297 
AVV30_gp030 
hypothetical 
protein 10049:10246 forward 198 
AVV30_gp031 
hypothetical 
protein 10248:10409 forward 162 
AVV30_gp032 
hypothetical 
protein 10411:10725 forward 315 
AVV30_gp033 
PF10947 family 
protein 10735:11154 forward 420 
AVV30_gp034 
putative 
lipoprotein 11151:11453 forward 303 
AVV30_gp035 
hypothetical 
protein 11450:11644 forward 195 
AVV30_gp036 
thymidylate 
synthase 11641:12492 forward 852 
AVV30_gp037 
hypothetical 
protein 12502:12678 forward 177 
AVV30_gp038 
hypothetical 
protein 12688:12810 forward 123 
AVV30_gp039 
hypothetical 
protein 12905:13105 forward 201 
AVV30_gp040 
hypothetical 
protein 13112:13327 forward 216 
AVV30_gp041 
hypothetical 
protein 13634:13960 forward 327 
AVV30_gp042 
hypothetical 
protein 14631:14792 forward 162 
AVV30_gp043 
hypothetical 
protein 14812:15123 forward 312 
AVV30_gp044 
hypothetical 
protein 15125:15601 forward 477 
AVV30_gp045 
hypothetical 
protein 15914:16054 forward 141 
AVV30_gp046 
hypothetical 
protein 16101:16556 forward 456 
AVV30_gp047 
PF11753 family 
protein 16553:16846 forward 294 
AVV30_gp048 
hypothetical 
protein 16849:17031 forward 183 
AVV30_gp049 
hypothetical 
protein 17045:17683 forward 639 
AVV30_gp050 
hypothetical 
protein 17744:18199 forward 456 
AVV30_gp051 
hypothetical 
protein 18827:19027 forward 201 
AVV30_gp052 
hypothetical 
protein 19129:19728 forward 600 
AVV30_gp053 
hypothetical 
protein 19959:20843 forward 885 
AVV30_gp054 
metallopeptidase 
domain protein 20900:22126 forward 1227 
AVV30_gp055 
hypothetical 
protein 22178:22372 forward 195 
AVV30_gp056 
hypothetical 
protein 22344:22535 forward 192 
AVV30_gp057 
hypothetical 
protein 22522:22701 forward 180 
AVV30_gp058 DNA helicase 22698:23858 forward 1161 
AVV30_gp059 
hypothetical 
protein 23860:24309 forward 450 
AVV30_gp060 DNA polymerase 24424:25992 forward 1569 
AVV30_gp061 
hypothetical 
protein 26109:26663 forward 555 
AVV30_gp062 
putative HNH 
homing 
endonuclease 27085:27618 forward 534 
AVV30_gp063 DNA polymerase 27878:28735 forward 858 
AVV30_gp064 
hypothetical 
protein 28811:29419 forward 609 
AVV30_gp065 
phosphoribosyl-
ATP 
diphosphatase 29469:29918 forward 450 
AVV30_gp066 
hypothetical 
protein 29918:30931 forward 1014 
AVV30_gp067 
hypothetical 
protein 30939:33104 forward 2166 
AVV30_gp068 
hypothetical 
protein 33108:33383 forward 276 
AVV30_gp069 
AAA domain 
protein 33399:34136 forward 738 
AVV30_gp070 
ssDNA binding 
protein 34198:34920 forward 723 
AVV30_gp071 
crossover 
junction 
endodeoxyribonu
clease RusA 34920:35717 forward 798 
AVV30_gp072 
hypothetical 
protein 35717:35914 forward 198 
AVV30_gp073 
hypothetical 
protein 35945:36148 forward 204 
AVV30_gp074 
viron-
encapsulated 
RNA polymerase 36190:45912 reverse 9723 
AVV30_gp075 
hypothetical 
protein 45912:47180 reverse 1269 
AVV30_gp076 
hypothetical 
protein 47183:47590 reverse 408 
AVV30_gp077 
hypothetical 
protein 47600:49804 reverse 2205 
AVV30_gp078 
hypothetical 
protein 49827:50303 reverse 477 
AVV30_gp079 
hypothetical 
protein 50306:50890 reverse 585 
AVV30_gp080 
major capsid 
protein 50947:52260 reverse 1314 
AVV30_gp081 
hypothetical 
protein 52273:53367 reverse 1095 
AVV30_gp082 
hypothetical 
protein 53371:53682 reverse 312 
AVV30_gp083 portal protein 53682:55799 reverse 2118 
AVV30_gp084 
hypothetical 
protein 55869:56156 forward 288 
AVV30_gp085 
hypothetical 
protein 56226:57311 reverse 1086 
AVV30_gp086 
hypothetical 
protein 57313:58980 reverse 1668 
AVV30_gp087 
hypothetical 
protein 58977:59663 reverse 687 
AVV30_gp088 
terminase large 
subunit 59671:61269 reverse 1599 
AVV30_gp089 
hypothetical 
protein 61262:61939 reverse 678 
AVV30_gp090 
hypothetical 
protein 61990:62178 forward 189 
AVV30_gp091 
hypothetical 
protein 62179:62310 forward 132 
AVV30_gp092 
hypothetical 
protein 62297:62434 forward 138 
AVV30_gp093 
hypothetical 
protein 62421:62564 forward 144 
AVV30_gp094 
hypothetical 
protein 62545:62679 forward 135 
AVV30_gp095 
hypothetical 
protein 62666:62779 forward 114 
AVV30_gp096 
hypothetical 
protein 62779:62895 forward 117 
AVV30_gp097 
hypothetical 
protein 63083:63274 forward 192 
AVV30_gp098 
hypothetical 
protein 63261:63386 forward 126 
AVV30_gp099 
hypothetical 
protein 63453:63611 forward 159 
AVV30_gp100 
hypothetical 
protein 63694:63870 forward 177 
AVV30_gp101 
hypothetical 
protein 63867:63998 forward 132 
AVV30_gp102 
hypothetical 
protein 63985:64116 forward 132 
AVV30_gp103 
hypothetical 
protein 64332:64472 forward 141 
AVV30_gp104 
hypothetical 
protein 64459:64599 forward 141 
AVV30_gp105 
hypothetical 
protein 64596:64820 forward 225 
AVV30_gp106 
hypothetical 
protein 64811:65005 forward 195 
AVV30_gp107 
hypothetical 
protein 64996:65208 forward 213 
AVV30_gp108 
hypothetical 
protein 65199:65384 forward 186 
AVV30_gp109 
hypothetical 
protein 65581:65802 forward 222 
AVV30_gp110 
hypothetical 
protein 65896:66393 reverse 498 
 
 
